Neutrophil gelatinase-associated lipocalin in prediction of mortality in patients with hepatorenal syndrome: a prospective observational study

Basit Öğe Kaydı
dc.contributor.authorGungor, Gokhan
dc.contributor.authorAtaseven, Huseyin
dc.contributor.authorDemir, Ali
dc.contributor.authorSolak, Yalcin
dc.contributor.authorGaipov, Abduzhappar
dc.contributor.authorBiyik, Murat
dc.contributor.authorOzturk, Bahadir
dc.date.accessioned2020-03-26T18:51:42Z
dc.date.available2020-03-26T18:51:42Z
dc.date.issued2014
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBackground & AimsHepatorenal syndrome (HRS) is a severe complication of cirrhosis which is characterized by renal dysfunction and associated with poor survival. Neutrophil gelatinase-associated lipocalin (NGAL) is a troponin-like biomarker for human acute kidney injury. We aimed to investigate levels of plasma and urine NGAL in HRS and predictive ability of these markers for all-cause mortality, in HRS, stable cirrhosis and control subjects. MethodsA total of 64 patients with cirrhosis (8 patients with type 1 HRS, 22 with type 2 HRS, and 34 without HRS) and 23 control subjects were included in the study. Blood and urine samples were measured with Human NGAL sandwich ELISA. Patients were followed up prospectively. ResultsPatients with type 1 and type 2 HRS had significantly higher plasma and urine NGAL levels compared with stable cirrhosis and control subjects. Cox regression analysis showed that plasma NGAL and MELD-Na scores were independent predictors of mortality. ROC-curve analysis showed that the plot of the plasma NGAL, urine NGAL, MELD-Na and Child-Turcot-Pugh score could predict all-cause mortality in cirrhotic patients' area under the curve (AUC 0.819, 0.686, 0.807 and 0.795 respectively). ConclusionsNGAL could predict mortality in patients with HRS independent of other commonly used risk factors.en_US
dc.description.sponsorshipERA-EDTA fellowship programme; Konya University Scientific Research Projects FundNecmettin Erbakan University [11102033]en_US
dc.description.sponsorshipG.A. received grant support from the ERA-EDTA fellowship programme. All authors had access to the data and played a role in writing this manuscript. This study was supported by Konya University Scientific Research Projects Fund (Project No: 11102033).en_US
dc.identifier.doi10.1111/liv.12232en_US
dc.identifier.endpage57en_US
dc.identifier.issn1478-3223en_US
dc.identifier.issn1478-3231en_US
dc.identifier.issue1en_US
dc.identifier.pmid23799980en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage49en_US
dc.identifier.urihttps://dx.doi.org/10.1111/liv.12232
dc.identifier.urihttps://hdl.handle.net/20.500.12395/31017
dc.identifier.volume34en_US
dc.identifier.wosWOS:000327977700009en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWILEYen_US
dc.relation.ispartofLIVER INTERNATIONALen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectacute kidney injuryen_US
dc.subjectcirrhosisen_US
dc.subjecthepatorenal syndromeen_US
dc.subjectmortalityen_US
dc.subjectneutrophil gelatinase-associated lipocalinen_US
dc.titleNeutrophil gelatinase-associated lipocalin in prediction of mortality in patients with hepatorenal syndrome: a prospective observational studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu